<DOC>
	<DOCNO>NCT02502864</DOCNO>
	<brief_summary>The purpose study adjust amount docetaxel participant receive base level docetaxel measure blood . This method dose adjustment call pharmacokinetic ( PK ) -adjusted docetaxel . The researcher believe adjust dose docetaxel use method lessen side effect associate docetaxel cancer treatment .</brief_summary>
	<brief_title>Multicenter Study Pharmacokinetic-Guided Docetaxel Breast Cancer Patients Receiving Docetaxel Cyclophosphamide</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Must histologically confirm localize locally advanced breast cancer treatment plan include chemotherapy 4 cycle standard TC ( docetaxel 75 mg/m^2 cyclophosphamide 600mg/m^2 ) Age &gt; /= 65 year ( Senior adult focus study give increase risk toxicity ) Participants must female Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Must normal organ marrow function No preexisting neuropathy grade &gt; 1 per NCI Common Toxicity Criteria Adverse Effects ( CTCAE ) version 4.0 Be postmenopausal ( define amenorrheic least 12 month ) Must inform investigational nature study willing provide write informed consent accordance Institutional guideline Good Clinical Practice ( GCP ) indicate understand purpose procedure require study willing participate prior begin specific study procedure . Have uncontrolled illness ( include , limited , ongoing active infection , congestive heart failure , angina pectoris , cardiac arrhythmia ) would limit compliance study requirement Have psychiatric illness would limit compliance study requirement Have history allergic reaction attribute compound similar chemical biologic composition taxanes ( docetaxel paclitaxel ) cyclophosphamide Have know seropositivity human immunodeficiency virus , hepatitis C virus , hepatitis B surface antigen , syphilis . Does require serologic confirmation study procedure . Not willing follow protocol requirement give informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>